US 12,409,140 B2
Therapeutic formulations and uses thereof
Dharam Paul, Eastwood (AU); Julia Crossman, Eastwood (AU); Elizabeth Doolin, Eastwood (AU); Tom Reynolds, Bend, OR (US); Xiangming Wu, Bend, OR (US); Jeff Millan, Bend, OR (US); Thomas Stumpfig, Bend, OR (US); and Kristie Downing, Bend, OR (US)
Assigned to Bionomics Limited, Eastwood (AU)
Appl. No. 17/641,020
Filed by Bionomics Limited, Eastwood (AU)
PCT Filed Feb. 17, 2020, PCT No. PCT/AU2020/050132
§ 371(c)(1), (2) Date Mar. 7, 2022,
PCT Pub. No. WO2021/056048, PCT Pub. Date Apr. 1, 2021.
Claims priority of provisional application 62/904,162, filed on Sep. 23, 2019.
Prior Publication US 2023/0147869 A1, May 11, 2023
Int. Cl. A61K 9/20 (2006.01); A61K 31/5377 (2006.01)
CPC A61K 9/2054 (2013.01) [A61K 9/2095 (2013.01); A61K 31/5377 (2013.01)] 15 Claims
 
1. A solid dispersion comprising a compound of formula (I) or a salt, or prodrug thereof;

OG Complex Work Unit Chemistry
dispersed within a polymer matrix formed by at least one pharmaceutically acceptable polymer, optionally with one or more pharmaceutically acceptable surfactants, wherein the pharmaceutically acceptable polymer is a crystallization inhibitor polymer which is a hydroxypropyl methylcellulose acetate succinate (HPMCAS),
and wherein the ratio of the compound of formula (I) or a salt thereof: crystallization inhibitor polymer is from 30:70 to 70:30 based on wt/wt % of the total solid dispersion, and wherein the solid dispersion comprises 50 mg-500 mg of the compound of formula (I) or salt thereof.